A phase II study of XELOX and Cetuximab (Erbitux) as first-line therapy in patients with KRAS wild-type metastatic colorectal cancer (FLEET2)

被引：0
|
作者：
Iwamoto, S. [1 ]
Hazama, S. [2 ]
Kin, H. [3 ]
Takemoto, H. [4 ]
Kobayashi, K. [5 ]
Takahashi, Y. [6 ]
Kobayashi, M. [7 ]
Maeda, H. [7 ]
Nagata, N. [8 ]
Oba, K. [9 ]
Sakamoto, J. [10 ]
Mishima, H. [1 ]
机构：
[1] Aichi Med Univ, Ctr Canc, Nagakute, Aichi, Japan
[2] Yamaguchi Univ, Dept Gastroenterol Breast & Endocrine Surg, Ube, Yamaguchi, Japan
[3] Rinku Gen Med Ctr, Dept Surg, Izumisano, Japan
[4] Kinki Cent Hosp, Dept Surg, Itami, Hyogo, Japan
[5] Matsunami Gen Hosp, Dept Surg, Hashima, Japan
[6] Hokkaido Canc Ctr, Dept Gastroenterol, Sapporo, Hokkaido, Japan
[7] Kochi Univ, Canc Treatment Ctr, Nankoku, Kochi, Japan
[8] Kitakyushu Gen Hosp, Kitakyushu, Fukuoka, Japan
[9] Univ Tokyo, Dept Epidemiol & Biostat, Tokyo, Japan
[10] Tokai Cent Hosp, Kakamigahara, Japan
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-157
引用
收藏
页码：46 / 46
页数：1
相关论文
共 50 条
  • [1] A Phase II Study of XELOX and Cetuximab as First-Line Therapy in Patients With KRAS Wild Type Metastatic Colorectal Cancer (FLEET2 Study)
    Hazama, Shoichi
    Maeda, Hiromichi
    Iwamoto, Shigeyoshi
    Kim, Ho Min
    Takemoto, Hiroyoshi
    Kobayashi, Kenji
    Sakamoto, Junichi
    Nagata, Naoki
    Oba, Koji
    Mishima, Hideyuki
    [J]. Clinical Colorectal Cancer, 2016, 15 (04) : 329 - 336
  • [2] Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study
    Hitoshi Soda
    Hiromichi Maeda
    Junichi Hasegawa
    Takao Takahashi
    Shoichi Hazama
    Mutsumi Fukunaga
    Emiko Kono
    Masahito Kotaka
    Junichi Sakamoto
    Naoki Nagata
    Koji Oba
    Hideyuki Mishima
    [J]. BMC Cancer, 15
  • [3] Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study
    Soda, Hitoshi
    Maeda, Hiromichi
    Hasegawa, Junichi
    Takahashi, Takao
    Hazama, Shoichi
    Fukunaga, Mutsumi
    Kono, Emiko
    Kotaka, Masahito
    Sakamoto, Junichi
    Nagata, Naoki
    Oba, Koji
    Mishima, Hideyuki
    [J]. BMC CANCER, 2015, 15
  • [4] Multicenter phase II study of FOLFOX or biweekly XELOX and cetuximab as first-line treatment in patients with wild-type KRAS/BRAF metastatic colorectal cancer (mCRC) (FLEET study)
    Kim, Ho Min
    Soda, Hitoshi
    Hazama, Shoichi
    Takahashi, Takao
    Nagata, Naoki
    Kotaka, Masahito
    Kono, Emiko
    Terada, Itsurou
    Fukunaga, Mutsumi
    Oba, Koji
    Hasegawa, Junichi
    Sakamoto, Junichi
    Mishima, Hideyuki
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [5] First-line cetuximab-based chemotherapies for patients with advanced or metastatic KRAS wild-type colorectal cancer
    Ohta, Katsuya
    Ikenaga, Masakazu
    Uemura, Mamoru
    Sakata, Kazuya
    Nishimura, Junichi
    Hata, Taishi
    Matsuda, Chu
    Mizushima, Tsunekazu
    Doki, Yuichiro
    Mori, Masaki
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 : 216 - 216
  • [6] First-line cetuximab-based chemotherapies for patients with advanced or metastatic KRAS wild-type colorectal cancer
    Uemura, Mamoru
    Kim, Ho Min
    Hata, Tsuyoshi
    Sakata, Kazuya
    Okuyama, Masaki
    Takemoto, Hiroyoshi
    Fujii, Hitoshi
    Fukuzaki, Takayuki
    Morita, Tetsushi
    Hata, Taishi
    Takemasa, Ichiro
    Satoh, Taroh
    Mizushima, Tsunekazu
    Doki, Yuichiro
    Mori, Maski
    [J]. MOLECULAR AND CLINICAL ONCOLOGY, 2016, 5 (02) : 375 - 379
  • [7] A PHASE II STUDY OF CETUXIMAB PLUS IRINOTECAN/S-1 AS FIRST-LINE TREATMENT IN KRAS WILD-TYPE METASTATIC COLORECTAL CANCER
    Masuishi, T.
    Sakai, Y.
    Matsui, T.
    Nakamura, R.
    Anzai, S.
    Suzuki, Y.
    Kobori, I.
    Fukami, Y.
    Suzuki, K.
    Tazawa, J.
    [J]. ANNALS OF ONCOLOGY, 2013, 24
  • [8] A phase II study of cetuximab in combination with irinotecan plus S-1 as first-line treatment in patients with KRAS wild-type metastatic colorectal cancer: CIRIS study
    Masuishi, T.
    Sakai, Y.
    Matsui, T.
    Nakamura, R.
    Anzai, S.
    Suzuki, Y.
    Kobori, I.
    Fukami, Y.
    Suzuki, K.
    Tazawa, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S557 - S557
  • [9] QUALITY OF LIFE ANALYSIS IN PATIENTS WITH KRAS WILD-TYPE METASTATIC COLORECTAL CANCER TREATED WITH FIRST-LINE FOLFIRI PLUS CETUXIMAB
    Lang, I.
    Koehne, C.
    Folprecht, G.
    Rougier, P.
    Curran, D.
    Hitre, E.
    Sartorius, U.
    Griebsch, I.
    Van Cutsem, E.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 191 - 192
  • [10] Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer
    Patel, Shiven B.
    Gill, David
    Garrido-Laguna, Ignacio
    [J]. ONCOTARGETS AND THERAPY, 2016, 9 : 75 - 86
12345